

ESMO24 Pre-Meeting New Drug Classification

OBiS Insights

OBiS Insights reports that ESMO24 will feature 2,960 new drugs, with 40% being antibodies and 37% being small molecules.

NEW YORK, NY, UNITED STATES, September 12, 2024 / EINPresswire.com/ -- OBiS Insights reports that ESMO24 will feature 2,960 new drugs, with 40% being antibodies and 37% being small molecules.

OBiS Insights ESMO24 New Drug Classification

40% (1090) Antibody: ADC (390), BsAb (320), mAb (210), ICI (170)

37% (1030) Small Molecule: Tyrosine Kinase Inhibitors (360), Other Kinase Inhibitors (220), Other Non Kinase Inhibitors (180), Protein Degradators/PPI/SERDs (90), CDK (90), KRAS (60), Other SMOL (30)


23% (630) Mixed Bag: Radiotherapeutics (180), Cell Therapy (160), Oncolytic Virus (100), Other Drug Conjugates (90), Other (60), Cancer Vaccine (40)

OBiS Insights reports that ESMO24 will feature 2,960 new drugs, with 40% being antibodies and 37% being small molecules.

OBiS Insights reports that ASCO24 will feature 1180 new drugs, with 43% being antibodies.

OBiS Insights reports that ASCO24 will feature 1180 new drugs, with 43% being antibodies.

OBiS Insights



ESMO24 - Pre-Meeting New Drug Classification

OBiS 0000 000 0 00 00 00 000, 00 00, 00, 000 00, 00 00 00 00, 00 00, 00 00 00 00, 0000 0000 0000 0000. OBiS 0000 AI 00 0000 00000 00000 0 00 0000 00000 000000. 20020, 00000 00000 00000 0000 00 00 000000 0 00000 00 0000000, 20200 0000 0000000000 00000 000000000.

00 00

0 00 0000 0000 0000 00 000000 00000, 00 00 0000 00 0000 0000000 0000 00000.

Richard Beasley

OBIS

+1 646-988-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/742660569>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.